GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Non Operating Income

Biogen (MEX:BIIB) Non Operating Income : MXN-2,588 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. Biogen's Non Operating Income for the three months ended in Dec. 2024 was MXN-2,453 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-2,588 Mil.

Biogen Non Operating Income Historical Data

The historical data trend for Biogen's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Non Operating Income Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,549.58 -16,825.58 16,517.01 -9,571.78 -2,715.41

Biogen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,009.75 -886.24 696.16 55.13 -2,452.63

Biogen Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2,588 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Non Operating Income Related Terms

Thank you for viewing the detailed overview of Biogen's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Non Operating Income
Comparable Companies
OGN AMRN SCLX MIRA LLY OCSE:NOVO B JNJ ABBV XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
BIIB:USA BIIB_KZ:Kazakhstan 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB:Chile BIIB34:Brazil BIIB:Austria BIIB:Argentina
Address
225 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.biogen.com
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.